Haematologica (Nov 2024)
Loncastuximab in high-risk and heavily pretreated relapsed / refractory diffuse large B-cell lymphoma: a real-world analysis from 21 US centers
- Viktoriya Zelikson,
- Ashwath Gurumurthi,
- Yazeed Sawalha,
- Kaitlin Annunzio,
- Aditi Saha,
- Ning Dong,
- David Qualls,
- Behzad Amoozgar,
- Brad Kahl,
- John Baird,
- Pavan Challa,
- Scott F Huntington,
- Jennifer Santos,
- Steven Bair,
- Mayur Narkhede,
- Shuning Li,
- Zachary Frosch,
- Carrie Ho,
- Stephen D Smith,
- Allison Winter,
- Daniel Landsburg,
- Fateeha Furqan,
- Mehdi Hamadani,
- Katelin Baird,
- Jason Romancik,
- Hanan Alharthy,
- Jennie Law,
- Leyla Bojanini,
- Ranjana Advani,
- Boyu Hu,
- Patrick Connor Johnson,
- Natalie S. Grover,
- Mwanasha Merril,
- Jennifer L. Crombie,
- Nazila Shafagati,
- Cole Sterling,
- Loretta J. Nastoupil,
- Narendranath Epperla,
- Emily C Ayers
Affiliations
- Viktoriya Zelikson
- University of Virginia Health System, Charlottesville
- Ashwath Gurumurthi
- MD Anderson Cancer Center, Houston, USA; Memorial Sloan Kettering Cancer Center, New York
- Yazeed Sawalha
- The Ohio State University Comprehensive Cancer Center, Columbus
- Kaitlin Annunzio
- The Ohio State University Comprehensive Cancer Center, Columbus
- Aditi Saha
- Moffit Cancer Center, Tampa
- Ning Dong
- Moffit Cancer Center, Tampa
- David Qualls
- Dana-Farber Cancer Institute, Boston
- Behzad Amoozgar
- Siteman Cancer Center, Washington University of St Louis, St. Louis
- Brad Kahl
- Siteman Cancer Center, Washington University of St Louis, St. Louis
- John Baird
- City of Hope Cancer Center, Los Angeles
- Pavan Challa
- Yale University, Yale Cancer Center, New Haven
- Scott F Huntington
- Yale University, Yale Cancer Center, New Haven
- Jennifer Santos
- University of Colorado Cancer Center, Anschutz Medical Campus, Denver
- Steven Bair
- University of Colorado Cancer Center, Anschutz Medical Campus, Denver
- Mayur Narkhede
- University of Alabama, Birmingham
- Shuning Li
- Fox Chase Cancer Center, Philadelphia
- Zachary Frosch
- Fox Chase Cancer Center, Philadelphia
- Carrie Ho
- Fred Hutchinson Cancer Center, Seattle
- Stephen D Smith
- Fred Hutchinson Cancer Center, Seattle
- Allison Winter
- Cleveland Clinic Cancer Center, Cleveland
- Daniel Landsburg
- Abramson Cancer Center, University of Pennsylvania, Philadelphia
- Fateeha Furqan
- Medical College of Wisconsin, Milwaukee
- Mehdi Hamadani
- Medical College of Wisconsin, Milwaukee
- Katelin Baird
- Winship Cancer Institute, Emory University, Atlanta
- Jason Romancik
- Winship Cancer Institute, Emory University, Atlanta
- Hanan Alharthy
- University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore
- Jennie Law
- University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore
- Leyla Bojanini
- Stanford Cancer Institute, Stanford
- Ranjana Advani
- Stanford Cancer Institute, Stanford
- Boyu Hu
- Hunstman Cancer Institute, University of Utah, Salt Lake City
- Patrick Connor Johnson
- Mass General Cancer Care, Massachusetts General Hospital, Boston
- Natalie S. Grover
- Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill
- Mwanasha Merril
- Dana-Farber Cancer Institute, Boston
- Jennifer L. Crombie
- Dana-Farber Cancer Institute, Boston
- Nazila Shafagati
- Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore
- Cole Sterling
- Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore
- Loretta J. Nastoupil
- MD Anderson Cancer Center, Houston
- Narendranath Epperla
- The Ohio State University Comprehensive Cancer Center, Columbus
- Emily C Ayers
- University of Virginia Health System, Charlottesville
- DOI
- https://doi.org/10.3324/haematol.2024.285977
- Journal volume & issue
-
Vol. 999,
no. 1
Abstract
Outcomes in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) are poor. Loncastuximab-teserine (Lonca) is an antibody drug conjugate (ADC) which was FDA approved for R/R DLBCL patients who have received at least 2 prior lines of therapy based on the LOTIS-2 trial. However, there are limited data regarding its efficacy in the real-world setting (RWS). This retrospective study included 21 US centers and evaluated outcomes of patients with R/R DLBCL treated with Lonca. Our analysis includes 187 patients with notably higher risk baseline features compared to LOTIS-2 including a higher proportion of patients with bulky disease (17% vs 0%), high-grade B-cell histology (HGBL) (22% vs 8%), and increased number of prior lines of therapy (median 4 vs 3). The complete response (CR) rate was 14% and overall response rate (ORR) was 32%. Median event free (EFS) and overall survival (OS) were 2.1 and 4.6 months, respectively. Those with bulky disease and HGBL had significantly worse outcomes, and those with non-germinal center cell of origin and CR to most recent line of therapy demonstrated superior outcomes. In summary, in this largest retrospective cohort study of Lonca in the RWS, the response rates, EFS, and OS were lower than those reported in LOTIS-2, which is likely reflective of its use in higher risk and more heavily pre-treated patients within the real world compared to those enrolled on clinical study.
